SEC Comment Letter 0000000000-23-009863 to ALX ONCOLOGY HOLDINGS INC (ALXO)
ALX ONCOLOGY HOLDINGS INC
Date: Sept. 6, 2023 · CIK: 0001810182 · Accession: 0000000000-23-009863
AI Filing Summary & Sentiment
File numbers found in text: 333-274314
Letter
United States securities and exchange commission logo September 6, 2023 Jaume Pons, Ph.D. Chief Executive Officer ALX Oncology Holdings Inc. 323 Allerton Avenue South San Francisco, CA 94080 Re:ALX Oncology Holdings Inc. Registration Statement on Form S-3 Filed September 1, 2023 File No. 333-274314 Dear Jaume Pons: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael E. Coke
Show Raw Text
United States securities and exchange commission logo
September 6, 2023
Jaume Pons, Ph.D.
Chief Executive Officer
ALX Oncology Holdings Inc.
323 Allerton Avenue
South San Francisco, CA 94080
Re:ALX Oncology Holdings Inc.
Registration Statement on Form S-3
Filed September 1, 2023
File No. 333-274314
Dear Jaume Pons:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Michael E. Coke